Rights Issue 2018

Intervacc, listed on Nasdaq First North, is a leading Nordic research company specializing in the development of veterinary vaccines, with its own sales and marketing organization in the Nordic and Baltic regions. Intervacc’s main product is the vaccine...

Rights Issue 2025

The Board of Directors has, pursuant to the authorization granted at the extraordinary general meeting on January 31, 2025, resolved to carry out an issue of a maximum of 265,076,924 new shares. Summary The purpose of the Rights Issue is to finance accelerated volume...